Thrombotic thrombocytopenic purpura (TTP) is a life-threatening systemic illness of abrupt onset and unknown cause. Proteolysis of the blood-clotting protein von Willebrand factor (VWF) observed in normal plasma is decreased in TTP patients. However, the identity of the responsible protease and its role in the pathophysiology of TTP remain unknown. We performed genome-wide linkage analysis in four pedigrees of humans with congenital TTP and mapped the responsible genetic locus to chromosome 9q34. A predicted gene in the identifed interval corresponds to a segment of a much larger transcript, identifying a new member of the ADAMTS family of zinc metalloproteinase genes (ADAMTS13). Analysis of patients' genomic DNA identi®ed 12 mutations in the ADAMTS13 gene, accounting for 14 of the 15 disease alleles studied. We show that de®ciency of ADAMTS13 is the molecular mechanism responsible for TTP, and suggest that physiologic proteolysis of VWF and/or other ADAMTS13 substrates is required for normal vascular homeostasis.
Thrombotic thrombocytopenic purpura (TTP) is a life-threatening systemic illness of abrupt onset and unknown cause. Proteolysis of the blood-clotting protein von Willebrand factor (VWF) observed in normal plasma is decreased in TTP patients. However, the identity of the responsible protease and its role in the pathophysiology of TTP remain unknown. We performed genome-wide linkage analysis in four pedigrees of humans with congenital TTP and mapped the responsible genetic locus to chromosome 9q34. A predicted gene in the identifed interval corresponds to a segment of a much larger transcript, identifying a new member of the ADAMTS family of zinc metalloproteinase genes (ADAMTS13). Analysis of patients' genomic DNA identi®ed 12 mutations in the ADAMTS13 gene, accounting for 14 of the 15 disease alleles studied. We show that de®ciency of ADAMTS13 is the molecular mechanism responsible for TTP, and suggest that physiologic proteolysis of VWF and/or other ADAMTS13 substrates is required for normal vascular homeostasis.
TTP is characterized by intravascular destruction of erythrocytes and blood platelets resulting in anaemia and thrombocytopenia. Diffuse platelet-rich microthrombi are observed in small blood vessels of multiple organs, with the major complications including renal failure and neurologic dysfunction. In the related disorder, haemolytic uraemic syndrome (HUS), neurologic symptoms are less evident and renal failure is more prominent. HUS is most frequently observed in young children, usually following infection with a speci®c Shiga-toxin-producing strain of Escherichia coli. Although TTP-like disorders have also been associated with various medications, bone marrow transplantation, pregnancy, human immunode®ciency virus (HIV) infection, and autoimmune disease, most cases appear sporadically, without an obvious precipitating event. A subset of patients from these sporadic cases experience a chronic relapsing course. Rare familial cases of TTP have also been reported, generally associated with neonatal onset and frequent relapses (OMIM (http://www.ncbi.nlm.nih.gov/Omim) (accession numbers 274150 and 276850) 1, 2 . Before the development of modern treatment protocols consisting of fresh-frozen plasma infusion with or without plasma exchange, fatality during an acute episode of TTP was .90% (refs 2 and 3). Although treatment outcome has improved signi®cantly, the molecular pathogenesis of TTP is still unknown and the speci®c plasma factor(s) responsible for the acute onset of this disease, or recovery after treatment, remains to be identi®ed. Unusually large multimeric forms of the platelet-adhesive blood-coagulation protein VWF have been observed in the plasma of TTP patients and are proposed to have a pathogenic role in the formation of the microvascular VWF-and platelet-rich thrombi characteristic of this disorder 4 . Consistent with this hypothesis, a proteolytic activity that degrades large VWF multimers to smaller sizes 5, 6 has been shown to be decreased in the plasma of TTP patients, either on the basis of a constitutional de®ciency in congenital cases or the presence of an autoantibody inhibitor in most sporadic adult-onset cases 7±10 . These ®ndings suggest that TTP may be triggered by accumulation of large, highly adhesive VWF multimers in the absence of physiologic processing by this VWF-cleaving protease. However, other studies have implicated platelet-aggregating proteins 11, 12 or endothelial injury 13 as the underlying mechanism, and enhanced rather than decreased VWF proteolysis has been reported in some patients 14 . Although the VWF-cleaving protease has been partially puri®ed 5, 6 , it seems to be present at relatively low levels in plasma and its identi®cation at the sequence level has remained elusive.
VWF-cleaving protease activity is a semidominant trait
To further explore the molecular pathogenesis of TTP, we used a genetic approach to study the four pedigrees shown in Fig. 1 . Activity of VWF-cleaving protease was measured in the plasma of the seven affected individuals, and was 2±7% of normal (0.02± 0.07 U ml -1 ); none of the patients tested positive for inhibitors of the protease. Plasma levels of the protease in the parents of the affected individuals were 0.51±0.68 U ml -1 , consistent with a heterozygous carrier state. Similarly, levels for at-risk siblings of the patients and parents fell into a bimodal distribution, with one peak consistent with carriers and the other indistinguishable from the normal distribution (Fig. 2 ). These results demonstrate that the protease activity assay used here reliably distinguishes between normal and carrier individuals in these families. This observation suggested that the plasma level of VWF-cleaving protease could be used as a phenotypic trait for linkage analysis to map the corresponding locus, providing considerably greater genetic power than would be available from analysis of the clinical phenotype alone.
Gene for familial TTP maps to chromosome 9q34
A genome-wide linkage scan was performed with 382 polymorphic microsatellite markers to analyse DNA from affected individuals and other informative family members (Fig. 1) . Two-point linkage analysis with a recessive model gave a maximum lod (log likelihood ratio) score of 2.36 at v = 0.0 for marker D9S164 on chromosome 9q34. A lod score of 5.63 at v = 0.0 was obtained for the same marker with a codominant model. There was still substantial evidence of linkage to D9S164 when a codominant model with 95% penetrance was used (lod score of 4.12 with v = 0.0 at D9S164). Multipoint analysis for D9S164 and four¯anking markers yielded a maximum lod score of 7.37 at marker D9S164. Genotypes for seven additional markers in this region 15, 16 allowed the gene to be placed in the ,7-centimorgan (cM) interval between markers D9S1863 and D9S1818 (Figs 1 and 3a) . Analysis of new polymorphic markers (see Supplementary Information Table 3 ) designed using simple sequence-repeat data available from the Human Genome Project working draft (http://genome.ucsc.edu) 17 further narrowed the candidate interval to an ,2.3-megabase (Mb) genomic segment between markers GL2-1 and D9S1818. In all but one case, carrier status as determined by haplotype analysis was consistent with the phenotypic designation according to plasma protease level. The exception, individual II2 in pedigree A, shares the affected haplotype of her brother (II4), but has a protease level of 0.8 U ml -1 , which is borderline between the normal and carrier ranges.
Gene for familial TTP encodes an ADAMTS metalloproteinase
Analysis of the candidate interval using public genome databases (http://genome.ucsc.edu, http://www.ncbi.nlm.nih.gov) 17 identi®ed ,20 known or predicted genes (Fig. 3a) . Initial attention focused on genes likely to encode a protease or protease cofactor. Ficolin 2 (FCN2) mapped to distal chromosome 9 but could not be identi®ed in available BAC sequence from the candidate interval. However, in light of previous reports suggesting a proteaseassociated function for some ®colin family members 18 , and the possibility that FCN2 might lie in one of the three large genomic sequence gaps shown in Fig. 3a boundaries of this gene were ampli®ed by polymerase chain reaction (PCR) from patients' DNA and subjected to sequence analysis. No candidate mutations were identi®ed. Two putative genes in the candidate interval, KIAA0605, an uncharacterized expressed sequence tag (EST) from a brain complementary DNA library 19 , and the predicted open reading frame C9ORF8, exhibited homology to the ADAMTS family of metalloproteinases, but seemed to lack the conserved protease catalytic domain. Partial DNA sequence analysis of exons and¯anking intron sequences failed to identify any mutations in KIAA0605. However, the identi®cation of several candidate missense mutations in the predicted exons of C9ORF8 led to further, more detailed analysis of this candidate gene. Through a combination of cDNA cloning, PCR with reverse transcription (RT-PCR), rapid ampli®cation of cDNA ends (RACE) and genomic sequence analysis, the full-length ADAMTS13 cDNA sequence (GenBank accession number AF414401) and corresponding genomic structure were deduced (Fig. 3b) and found to encode a complete, potentially catalytically active ADAMTS protease.
Members of the ADAM (a disintegrin and metalloproteinase) family are membrane-anchored proteases with diverse functions. Known members include fertilins a and b, implicated in sperm±egg fusion, and the`sheddases' , such as TACE (TNF-a convertase), which mediate the shedding of cell-surface proteins 20 . Members of the ADAMTS family are distinguished from ADAMs by the presence of one or more thrombospondin-1-like (TSP1) domain(s) at the carboxy terminus, which are thought to mediate interactions with components of the extracellular matrix 21±24 . In addition, ADAMTS proteins lack the EGF repeat, transmembrane domain and cytoplasmic tail typically observed in ADAM metalloproteinases. Mutations in ADAMTS2 (procollagen N-proteinase), the only family member previously associated with a human genetic disease, result in the connective tissue disorder, Ehlers-Danlos syndrome type VII (ref. 25) . Although ADAMTS1 mutations have not been identi®ed in humans, genetically de®cient mice exhibit growth retardation, adipose tissue abnormalities, and ®brotic changes throughout the genitourinary system, suggesting a critical importance for ADAMTS1 in organogenesis and tissue remodelling 26 . ADAMTS4 and ADAMTS5/11 (aggrecanases) cleave the core protein of the cartilage proteoglycan, aggrecan, and may be important in in¯am-matory joint disease 27 . Procollagen II has recently been identi®ed as the substrate for ADAMTS3 (ref. 28) . The function and protein substrates for the remaining ADAMTS family members are unknown.
The ADAMTS13 gene spans 29 exons encompassing ,37 kb in the human genome and encodes a protein with 1,427 amino acids (Fig. 3b) . Analysis of RT-PCR and cloned cDNA sequences provided evidence for alternative splicing of exon 17 (GenBank accession number AF414400), resulting in a frameshift that predicts a truncated 842-amino-acid form of the protein lacking the six C-terminal TSP1 repeats. Comparative analysis with draft mouse genomic sequences demonstrates a high degree of conservation throughout the coding exons and identi®es an additional potential exon located between the current exons 22 and 23, which may indicate another splice isoform. These ®ndings suggest the potential for differentially regulated alternative isoforms of ADAMTS13 with diverse biological functions in addition to the putative proteolytic processing of VWF. Alternative splicing has been observed for two other ADAMTS genes, ADAMTS2 (ref. The domain structure of ADAMTS13 is depicted at the bottom of Fig. 3b . A predicted signal peptide is followed by a short propeptide domain ending in a potential propeptide convertase cleavage site at amino acids 71±74 (RQRR), suggesting that proteolytic processing, either in the trans Golgi or at the cell surface, is required for activation. The protease domain that follows contains a perfect match for the HEXGHXXGXXHD (where X is any amino acid) consensus sequence of the extended catalytic site shared between snake venom metalloproteinases and ADAM family members 20, 21, 29 . The catalytic domain is followed by TSP1 and spacer domains characteristic of the ADAMTS family. An RGD sequence, present in only one other mature ADAMTS protein (ADAMTS2), is located immediately C terminal to the ®rst TSP1 domain of ADAMTS13, suggesting a possible integrin interaction. The C terminus contains six additional TSP1 repeats, followed by a segment with homology to the CUB domain identi®ed in a number of developmentally regulated proteins 30 . The previously reported inhibitor pro®le and metal cation dependence of the VWF-cleaving protease 5, 6, 31 are consistent with its identity as an ADAMTS. The predicted, nonglycosylated relative molecular mass of ADAMTS13 is 154,000 (M r 154K), consistent with a previously estimated M r of 200K for partially puri®ed VWF-cleaving protease 5 , although considerably smaller than the 300K M r reported by others 6 . Northern blot analysis detected an ADAMTS13 messenger RNA of ,4.7-kb speci®cally in the liver, with a truncated (,2.3 kb) mRNA faintly visible in the placenta (Fig. 4a) . These data suggest that plasma VWF-cleaving protease may be derived primarily from ADAMTS13 expression in the liver. The strong RT-PCR signal seen in the ovary, and variable expression in other tissues (Fig. 4b) , may point to other potential functions for this protein. The absence of detectable transcripts in other highly vascular tissues such as the lung and heart may indicate that the vascular endothelium is not a primary site of ADAMTS13 expression.
Mutations in ADAMTS13 cause familial TTP
Analysis of DNA sequences identi®ed mutations within the ADAMTS13 gene in all four of the pedigrees depicted in Fig. 1 , as well as in three additional TTP patients not included in the original , respectively, and no detectable inhibitor. The parents of proband E had VWF-cleaving protease levels of 0.49 and 0.63 U ml -1 and the parents of proband G had levels of 0.53 and 0.68 U ml -1 .
genome scan (families E±G, Table 1 ). The 12 mutations identi®ed account for all but one of the 15 disease alleles expected in this set of patients (Table 1 and Fig. 5 , and see Supplementary Information Figs 6 and 7). No recurrent mutation was observed, except in family A (Fig. 5) . All three affected individuals in this family are homozygous for the same mutation carried on the same extended haplotype (data not shown), suggesting recent common ancestry. Although there is no known consanguinity, the parents of affected individuals AIII-2, AIII-3 and AIII-8 are all from the same small village where the families have lived for several generations. Two of the 12 identi®ed mutations result in frameshifts (a 26-base pair (bp) deletion in exon 19 (Fig. 5) and a single T insertion in exon 27). A single splice mutation was identi®ed in one family (1584 + 5G ! A, family G). This substitution markedly reduces or eliminates utilization of the normal intron 13 splice donor and activates a cryptic donor splice site at +70, resulting in a 23-codon insertion (see Supplementary Information Fig. 6 ). The remaining nine mutations all result in nonconservative amino-acid substitutions (Table 1) and all occur at positions that are perfectly conserved between the human and murine genes. H96D in the catalytic domain and R398H in the ®rst TSP1 domain both alter residues that are almost perfectly conserved among all known ADAMTS family members. All 12 of the ADAMTS13 gene mutations described above were excluded as common sequence polymorphisms by screening a large panel of unaffected chromosomes. Many single-nucleotide polymorphisms (SNPs) were also identi®ed, although only 7 of 25 result in amino-acid substitutions (see Supplementary Information Table 2 ).
The spectrum of ADAMTS13 mutations observed here is notable for the relative paucity of obvious null alleles. In addition, the single splice mutation and two frameshift mutations all occur in trans with a missense mutation on the other allele. These data suggest that complete de®ciency of ADAMTS13 may be lethal, consistent with the low levels of residual VWF-cleaving protease activity observed in all ten de®cient patients studied here (0.02±0.09 U ml For mutations in families A±D, candidate mutations were con®rmed in both parents. All mutations were con®rmed as absent from ,180 control normal chromosomes by PCR, allele-speci®c oligonucleotide hybridization or restriction digest.
Discussion
The ®ndings reported here identify genetic de®ciency of ADAMTS13 as the underlying molecular mechanism responsible for most or all cases of familial TTP. This disorder seems to be identical to the congenital microangiopathic haemolytic anaemia also referred to as Schulman-Upshaw syndrome 32 (OMIM number 276850). Although symptomatic anaemia and thrombocytopenia are usually present at birth, two of the patients studied here (proband G and BII-2) did not experience their ®rst episodes of TTP until the ages of 4 and 8 years, respectively, despite clinical disease as neonates in siblings of both individuals. This highly variable age of onset, even within the same family, suggests a major contribution of other genetic and/or environmental modifying factors that remain to be identi®ed. Previous studies have demonstrated antibody inhibitors directed against the VWF-cleaving protease in most adult TTP patients, suggesting an autoimmune aetiology 7, 10 . However, the late onset of this disorder observed in two of the ten patients in our series raises the possibility that a subset of apparently sporadic adult-onset TTP may be due to unrecognized recessive inheritance of ADAMTS13 mutations.
The nearly perfect correlation of plasma VWF-cleaving protease activity with TTP carrier status that we observed was critical to the success of the genetic linkage analysis reported here. Although these data indicate that the plasma levels of this protease activity are very tightly regulated, to date no clinical phenotype has been detected in previously reported familial TTP carriers, or in any of the ADAMTS13-mutation heterozygotes identi®ed here. However, the presence of a subtle phenotype in these individuals, such as increased susceptibility to thrombosis or to one or more of thè acquired' forms of TTP, cannot be excluded.
Our data provide the ®rst direct evidence of an aetiologic role for VWF-cleaving protease activity in the pathogenesis of TTP and identify the enzyme likely to be responsible for this activity: metalloproteinase ADAMTS13. Physiologic cleavage of VWF at the Tyr 842±Met 843 peptide bond produces the characteristic 176K proteolytic fragment observed in normal plasma 5, 6, 33 and increased susceptibility to this proteolytic cleavage seems to be responsible for the loss of large VWF multimers central to the pathophysiology of type 2A von Willebrand disease (VWD) 31, 34 . Taken together with previous work from our group and others 4±7,10 , our data strongly suggest that ADAMTS13 is the VWF-cleaving protease itself. However, we cannot exclude the possibility that ADAMTS13 acts on VWF indirectly, perhaps by activating another protease. In either case, our data are consistent with the hypothesis that accumulation of large, hyperactive VWF multimers in the absence of normal proteolytic processing triggers pathologic platelet aggregation and is the direct mechanism responsible for TTP. Alternatively, decreased VWF proteolysis could solely be a marker for the loss of ADAMTS13 activity. ADAMTS13 may also have important biological functions elsewhere in the coagulation system or in the blood vessel wall, with loss of one or more of these activities providing the direct link to the pathogenesis of TTP. Future studies of ADAMTS13 function, both in vivo and in vitro, should answer these questions and provide insight into the complex biological processes regulating haemostasis and the maintenance of vascular integrity. Finally, the identi®cation of ADAMTS13 de®ciency as the cause of TTP also has major implications for the treatment of this important human disease, including the potential for production of recombinant ADAMTS13 as a safer and more effective replacement for current plasma-exchange therapy. Note added in proof: Fujikawa et al. 35 and Gerritsen et al. 36 have reported puri®cation and sequence analysis of the amino-terminal amino acids of human VWF-cleaving protease. These results con®rm the identity of ADAMTS13 as the VWF-cleaving protease and its predicted processing by propeptide convertase cleavage.
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Methods Subjects
Patients included in this study were referred for evaluation of thrombocytopenia, haemolytic anaemia and schistocytes on blood smear. Probands for the four families (A±D) used in the linkage analysis all had a chronic relapsing course, responded to plasma infusion, and had the disorder as neonates or had a family member with such a disorder as a neonate. All three probands for kindreds E±G also had microangiopathic haemolysis and/or thrombocytopenia noted soon after birth or in the early neonatal period (in the patient or an affected sibling), along with clinical response to plasma infusion.
Plasma samples were obtained from sodium citrate anticoagulated blood by centrifugation and saved at -70 8C as previously described 7 . Mononuclear cells were obtained from heparin anticoagulated blood by centrifugation on Ficoll-Hypaque, washed and transformed with Epstein-Barr virus. Informed consent was obtained from all individuals before sample collection (study protocol approved by the institutional review board).
Multimer analysis and VWF-cleaving protease activity
Analysis of VWF multimers was performed as previously described 7 . Ultra large VWF multimers were detected in the plasma of all TTP patients studied, with normal patterns observed in all other family members. For the measurement of VWF-cleaving protease activity, VWF treated with guanidine hydrochloride was used as the substrate. Protease activity was represented by the optical density of the dimer of the 176K fragment generated from the VWF substrate 7 and was expressed in units per millilitre, with the activity measured in pooled normal control plasma de®ned as 1 U ml -1 . Protease activity is reported as the mean of two measurements for the parents of families E and G. All other samples were measured on at least three occasions, with the mean value reported. Assays for inhibitors of VWF-cleaving protease were performed as described 37 .
Linkage analysis
A genome-wide linkage screen was performed with 382 polymorphic microsatellite markers spaced an average of 10 cM (panels 1±27 of the ABI Prism Linkage Mapping Set-MD10 (Applied Biosystems)). We ampli®ed 20 ng of genomic DNA with AmpliTaq Gold DNA polymerase (Applied Biosystems). PCR products were run on an ABI Prism 3700 DNA Analyzer and analysed with Genescan version 3.5NT and Genotyper version 3.6NT. Inspection of the pedigrees indicated an autosomal recessive mode of inheritance for TTP in this set of families. The frequency of the disease gene was assumed to be 1 per 10,000 chromosomes in the population. Population frequencies of the marker alleles were estimated from the genotyped individuals. Two-point lod scores were calculated with the program MLINK as implemented in the FASTLINK package version 3.0 (ref. 38) , with an autosomal recessive model. A second series of analyses was performed with a codominant model to re¯ect the lowered enzyme levels of individuals who were assumed to be carriers of the disease gene. For the latter analysis, individuals were classi®ed as affected (those with clinical diagnoses), carriers (those with protease levels in the range of 0.45±0.68 U ml ) and unaffected (those with protease levels in the range of 0.9±1.17 U ml -1 ). One individual (AII-2), whose protease level was intermediate between the carrier and unaffected ranges, was classi®ed as phenotype unknown. Penetrance was set at 100% for the recessive model and codominant models. Consistency of the linkage evidence was evaluated by recomputing the lod score with 95% penetrance for the codominant model. Multipoint analyses were performed with the program VITESSE 39 , using the same two disease models and the ®ve markers at or¯anking the maximum two-point lod score (centromere-D9S1682-D9S290-D9S164-D9S1826-D9S158-telomere). Order and distances between markers were determined with the ABI Prism Linkage Mapping Set-MD10 map information. To ensure the multipoint analyses were computationally feasible, the number of founders in pedigree A was reduced and less-informative individuals (II-1, -2, -3 and -13, and III-8 and -9) were pruned from the pedigree.
